Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
http://www.tandfonline.com/doi/pdf/10.1080/10428190500063229
Reference14 articles.
1. Late Cardiac Toxicity of Doxorubicin, Epirubicin, and Mitoxantrone Therapy for Hodgkin's Disease in Adults
2. Randomized study for the treatment of adult advanced Hodgkin's disease: Epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD)
Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Survivorship care for patients curatively treated for Hodgkin’s and non-Hodgkin’s lymphoma: a scoping review;Journal of Cancer Survivorship;2023-12-04
2. Nuclear Imaging for the Assessment of Cardiotoxicity from Chemotherapeutic Agents in Oncologic Disease;Current Cardiology Reports;2021-05-07
3. Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review;Expert Review of Hematology;2020-08-02
4. Hodgkin lenfoma sonrası kalpte ve akciğerde görülen geç yan etkiler;Cukurova Medical Journal;2019-12-30
5. Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin’s disease;Radiation Oncology;2019-09-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3